Silk Road Medical Expands TCAR® Portfolio with Launch of Tapered ENROUTE® Transcarotid Stent System
06 March 2024 - 1:00AM
Silk Road Medical, Inc. (Nasdaq: SILK), a company focused on
reducing the risk of stroke and its devastating impact, today
announced that it has launched its Tapered ENROUTE Transcarotid
Stent System to hospitals in the United States. This launch expands
upon the company’s prior ENROUTE Transcarotid Stent System,
offering additional configurations to better tailor the
Transcarotid Artery Revascularization (TCAR) procedure to patient
anatomy. TCAR is a minimally invasive, surgical procedure designed
to provide best-in-class stroke protection while minimizing adverse
events.
“As pioneers in stroke prevention, our product
development efforts are focused on extending our lead in the
minimally invasive treatment of carotid artery disease,” said Chas
McKhann, Chief Executive Officer of Silk Road Medical. “New
tapered configurations for our ENROUTE Transcarotid Stent System
build upon the robust portfolio of Silk Road’s carotid solutions.
We are pleased to bring this portfolio expansion to market as part
of our commitment to offering a diverse toolkit for physicians,
allowing them to address individual patient anatomy.”
The ENROUTE Transcarotid Stent System is the only
commercially available transcarotid stent system indicated for
patients at high risk and standard risk for adverse events from
carotid endarterectomy (CEA). The ENROUTE Transcarotid Stent System
features an optimized cell design balancing lesion coverage and
anatomical conformability for long-term plaque stabilization. The
stent system was purpose-built for TCAR with a short delivery
system for ergonomic and precise stent delivery.
“The new tapered stent is a welcome addition to my
TCAR toolkit, further differentiating the Company’s core product
offering,” said Joseph V. Lombardi, MD, MBA, FACS, Professor and
Chief of Vascular Surgery, Cooper University Health Care. “The
ENROUTE stent has always provided comprehensive lesion coverage and
durable procedural outcomes, but I now have more options to
customize treatment to each patient's anatomy.”
For more information on the ENROUTE Transcarotid
Stent System, visit:
https://silkroadmed.com/healthcare-professionals/products/enroute-transcarotid-stent-system/
About TCAR with the ENROUTE Transcarotid
Neuroprotection and Stent SystemTCAR (TransCarotid Artery
Revascularization) is a clinically proven procedure combining
surgical principles of neuroprotection with minimally invasive
endovascular techniques to treat blockages in the carotid artery at
risk of causing a stroke. The ENROUTE Transcarotid Stent is
intended to be used in patients at high risk and standard risk for
complications from CEA, in conjunction with the ENROUTE
Transcarotid Neuroprotection System (NPS) during the TCAR
procedure. The ENROUTE Transcarotid NPS is a first in class device
used to directly access the common carotid artery and initiate
high-rate temporary blood flow reversal to protect the brain from
stroke while delivering and implanting the ENROUTE Transcarotid
Stent.
About Silk Road Medical Silk
Road Medical, Inc. (NASDAQ: SILK), is a medical device company
with locations in Sunnyvale, California, and Plymouth,
Minnesota, that is focused on reducing the risk of stroke and its
devastating impact. The company has pioneered a new approach for
the treatment of carotid artery disease called TransCarotid Artery
Revascularization (TCAR). TCAR is a clinically proven procedure
combining surgical principles of neuroprotection with minimally
invasive endovascular techniques to treat blockages in the carotid
artery at risk of causing a stroke. For more information on how
Silk Road Medical is delivering brighter patient outcomes through
brighter thinking, visit www.silkroadmed.com and connect on
Twitter, LinkedIn and Facebook.
Investors:Marissa BychGilmartin
Groupinvestors@silkroadmed.com
Media:Michael FanucchiSilk Road
Medicalmfanucchi@silkroadmed.com
Silk Road Medical (NASDAQ:SILK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Silk Road Medical (NASDAQ:SILK)
Historical Stock Chart
From Apr 2023 to Apr 2024